Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer

• Status: Completed
• Trial end date: 2019-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to to investigate the effect of tocotrienol as a nutritional supplement in combination with bevacizumab in patients with advanced ovarian cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vejle Hospital
• Treatments: Bevacizumab; Tocopherols; Tocotrienols; Vitamin E

Criteria

Inclusion Criteria:

• Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer.

• Prior treatment with at least two different cytostatic regimens including platinum.

• Progression on previous treatment.

• Measurable disease by RECIST 1.1 or evaluable by GCIG CA-125 criteria.

• Age ≥ 18 years.

• Performance stage 0-2.

• Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion):

• WBC ≥ 3.0 * 10^9/l or neutrophils (ANC) ≥ 1.5 * 109/l

• Platelet count ≥ 100 * 10^9/l

• Hemoglobin ≥ 6 mmol/l

• Serum bilirubin < 2.0 * ULN

• Serum transaminase ≤ 2.5 * ULN

• Serum creatinine ≤ 1.5 ULN

• Urine dipstick for protein <2+. If the dipstick shows protein ≥2+ 24 hour urine testing must be made with protein contents < 1 g.

• Written informed consent.

Exclusion Criteria:

• Other malignant diseases within 5 years prior to inclusion in the study, except curatively treated basal cell or squamous cell carcinoma of the skin and other types of cancer with minimal risk of recurrence.

• Other experimental therapy or participation in another clinical trial within 28 days prior to treatment initiation.

• Underlying medical disease not adequately treated (diabetes, cardiac disease).

• Uncontrolled hypertension (BT >150/100 despite antihypertensive treatment).

• Surgery, incl. open biopsy, within 4 weeks prior to first dose of bevacizumab.

• Non-healing wounds or fractures.

• Cerebral vascular attack, transient ischemic attack or subarachnoidal hemorhage within 6 months before start of treatment.

• Clinically significant cardiovascular disease, including:

• Myocardial infarction or unstable angina within 6 months before start of treatment

• New York heart Association (NYHA) class ≥ 2

• Poorly controlled cardiac arrhythmia despite medication

• Periferal vascular disease grade ≥ 3

• Allergy to the active substance or any of the auxiliary agents

• Bleeding tumor

• Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at screening is mandatory.

• Fertile patients not willing to use effective methods of contraception during treatment and for 6 months after the end of treatment